ArticleIranian journal of public health2022
Epidemiological Characteristics of Male Reproductive Cancers in the Republic of Kazakhstan: Ten-Year Trends.
Article in Iranian journal of public health, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Fear of Cancer Progression as a Psychological Component of Cancer Rehabilitation in Men Treated for Reproductive System Malignancies: A Multi-Regional Cross-Sectional Study in Kazakhstan.Healthcare (Basel, Switzerland) · 2026Article
- The Evolving Role of Chemotherapy in the Management of Pleural Malignancies: Current Evidence and Future Directions.Cancers · 2025Review
- DRG payment for male reproductive system malignant tumor surgery: analysis and recommendations on resource consumption in a tertiary hospital in China.BMC surgery · 2025Article
- A Study of the Effectiveness of Apoptosis Biomarkers in the Diagnosis of Gastric Cancer in Kazakhstan: A Review of Systematic Evidence.Medical journal of the Islamic Republic of Iran · 2025Review
- Burden of major cancer types in Almaty, Kazakhstan.Scientific reports · 2024Article
- Trends of Prostate Cancer Morbidity in Low-Incidence Countries from 1990-2019.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiology of male reproductive cancers (MRC) is relatively well studied in developed world nations, but little is known about Central Asian states. We aimed to analyze the changing trends for incidence, mortality and 5-year survival MRC across provinces of the Republic of Kazakhstan. Methods: This was a retrospective cohort study based on data obtained from the Kazakhstan Cancer Registry, which serves as a nationwide database for all histologically confirmed cancer cases. From this, information on all male patients with prostate (PCa) and testicular cancers (TCa) was retrieved for the period from 2010 to 2019. The statistical analysis of official data on incidence, survival, and mortality rates was performed for both the whole country and its provinces. Results: There was a substantial instability of PCa incidence rates, attributed to the execution of screening program from 2013 to 2017. Still, there was a lack of variations in TCa incidence rates. However, PCa screening program had no influence on reduction of mortality rates, which remained relatively stable. There is much heterogeneity between country's provinces in incidence and mortality rates. TCa patients were younger than PCa patients and had better 5-year survival. Conclusion: As compared with many other countries, Kazakhstani men with PCa and TCa have poorer five-year survival, which requires further investigation. Moreover, a careful analysis of diagnostic and treatment strategies utilized at different hospitals across the country would be highly desirable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.